Online citations, reference lists, and bibliographies.
← Back to Search

Development Of A Highly Multiplexed SRM Assay For Biomarker Discovery In Formalin-Fixed Paraffin-Embedded Tissues.

Carine Steiner, P. Lescuyer, Jean-Christophe Tille, Paul Cutler, A. Ducret
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The search for novel and clinically relevant biomarkers still represents a major clinical challenge and mass-spectrometry-based technologies are essential tools to help in this process. In this application, we demonstrate how selected reaction monitoring (SRM) can be applied in a highly multiplexed way to analyze formalin-fixed paraffin-embedded (FFPE) tissues. Such an assay can be used to analyze numerous samples for narrowing down a list of potential biomarkers to the most relevant candidates. The use of FFPE tissues is of high relevance in this context as large sample collections linked with valuable clinical information are available in hospitals around the world. Here we describe in detail how we proceeded to develop such an assay for 200 proteins in breast tumor FFPE tissues. We cover the selection of suitable peptides, which are different in FFPE compared to fresh frozen tissues and show how we deliberately biased our assay toward proteins with a high probability of being measurable in human clinical samples.
This paper references
10.1016/j.semcdb.2016.08.026
Cancer heterogeneity determined by functional proteomics.
A. Szasz (2017)
10.1016/j.molonc.2015.09.002
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy
P. Nuciforo (2016)
10.1586/epr.13.3
Proteomic studies of formalin-fixed paraffin-embedded tissues
L. Giusti (2013)
10.1016/j.ctrv.2016.12.005
Strategies to design clinical studies to identify predictive biomarkers in cancer research.
José Luis Pérez-Gracia (2017)
10.1038/nrc2113
Shaping the future of biomarker research in breast cancer to ensure clinical relevance
M. Hinestrosa (2007)
10.1093/jnci/djt376
Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer
N. Q. Liu (2014)
10.1002/PMIC.200600016
Mass spectrometric analysis of formalin‐fixed paraffin‐embedded tissue: Unlocking the proteome within
B. Hood (2006)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
10.1016/j.clinbiochem.2012.10.002
The proteomics of formalin-fixed wax-embedded tissue.
David Cilia Vincenti (2013)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
10.3748/wjg.v22.i26.5896
Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.
M. Matboli (2016)
10.1074/mcp.M113.036095
Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach*
S. Carr (2014)
10.1038/msb.2008.61
Selected reaction monitoring for quantitative proteomics: a tutorial
V. Lange (2008)
10.1002/pmic.201100463
Using iRT, a normalized retention time for more targeted measurement of peptides
Claudia Escher (2012)
10.1074/mcp.M800518-MCP200
Equivalence of Protein Inventories Obtained from Formalin-fixed Paraffin-embedded and Frozen Tissue in Multidimensional Liquid Chromatography-Tandem Mass Spectrometry Shotgun Proteomic Analysis*
Robert W. Sprung (2009)
10.1200/JCO.2008.18.1370
Supervised risk predictor of breast cancer based on intrinsic subtypes.
J. Parker (2009)
10.1074/mcp.O115.049049
Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues*
Carine Steiner (2015)
10.1186/bcr3035
A clinically relevant gene signature in triple negative and basal-like breast cancer
A. Rody (2011)
10.1177/002215549804600314
Extraction and Analysis of Diagnostically Useful Proteins from Formalin-fixed, Paraffin-embedded Tissue Sections
K. Ikeda (1998)
10.1016/j.eururo.2016.08.024
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
C. Barbieri (2017)
10.1158/0008-5472.CAN-07-5644
Subtypes of breast cancer show preferential site of relapse.
M. Smid (2008)
10.1136/jclinpath-2012-201361
Therapeutic targets in triple negative breast cancer
S. O’Toole (2013)
10.1002/pmic.200800351
Peptide separation with immobilized pI strips is an attractive alternative to in‐gel protein digestion for proteome analysis
Nina C. Hubner (2008)
10.1093/bioinformatics/btq054
Skyline: an open source document editor for creating and analyzing targeted proteomics experiments
B. MacLean (2010)
10.1021/PR050208P
Efficient method for the proteomic analysis of fixed and embedded tissues.
D. Palmer-Toy (2005)
10.1021/ac102179j
Effect of collision energy optimization on the measurement of peptides by selected reaction monitoring (SRM) mass spectrometry.
B. MacLean (2010)
10.1002/pmic.201100533
Highly multiplexed targeted proteomics using precise control of peptide retention time
S. Gallien (2012)
10.1021/ac701680f
Genome-specific gas-phase fractionation strategy for improved shotgun proteomic profiling of proteotypic peptides.
Alexander Scherl (2008)
10.1016/j.jmoldx.2013.03.002
Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue.
Todd Hembrough (2013)
10.1038/nrm1683
Scoring proteomes with proteotypic peptide probes
B. Kuster (2005)
10.1371/journal.pone.0100586
Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue
D. Catenacci (2014)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar